French Aerospace & Defense Stock News

Renault has launched a new group plan called "futuREady" that targets 36 new model launches by 2030. The plan puts more weight on electrification, product development and partnerships across Renault’s ecosystem. A key element is a stronger push beyond Renault’s traditional European strongholds to capture more international growth. For investors watching ENXTPA:RNO, this fresh plan lands at a time when the shares trade around €28.17 and have faced pressure, with a 1 year return of a 38.1%...

Vusion (ENXTPA:VU) has been in focus after reporting 2025 sales of €1,472 million with net income of €84.2 million, issuing 2026 earnings guidance, and outlining an AI retail partnership with Qualcomm. See our latest analysis for Vusion. Despite the recent earnings, 2026 guidance and Qualcomm AI retail partnership, Vusion’s 30 day share price return of 12.12% and year to date share price return of 46.94% suggest momentum has been weak, even though the 5 year total shareholder return of...

Why Ipsen Stock Is On Investors’ Radar Ipsen (ENXTPA:IPN) has drawn attention after a solid recent share price run, with the stock showing positive returns over the month and past 3 months, prompting closer inspection of its fundamentals. See our latest analysis for Ipsen. The latest move to €157.1 comes after a 15.43% 1 month share price return and a 29.30% 3 month share price return, set against a 46.21% 1 year total shareholder return and 146.66% 5 year total shareholder return that signal...

Séché Environnement (ENXTPA:SCHP) has just reported its FY 2025 first half with revenue of €612.9 million and basic EPS of €2.05, setting the tone for how investors assess the latest leg of its earnings story. Over recent periods, revenue has moved from €540.5 million and EPS of €1.02 in 1H 2024 to €649.9 million and EPS of €3.57 in 2H 2024. Trailing twelve month EPS for 1H 2025 sits at €5.61 on revenue of about €1.3 billion, which frames today’s numbers against a much larger revenue base...

DBV Technologies (ENXTPA:DBV) recently reported additional positive data from its Phase 3 VITESSE trial of the VIASKIN Peanut Patch in peanut allergic children, with the study meeting its primary endpoint and showing a statistically significant treatment effect. See our latest analysis for DBV Technologies. The latest clinical update appears to be feeding into stronger momentum, with a 7.3% 1 day share price return and a 36.95% 90 day share price return at €4.04, alongside a very large 1 year...

Why this new AI and UWB push matters for STMicroelectronics STMicroelectronics (ENXTPA:STMPA) has moved into high-volume production of its silicon photonics PIC100 platform for AI data centers while also unveiling a new ultra-wideband chip family for precise localization in cars and connected devices. For you as an investor, these parallel moves bring the focus squarely onto how much value the market assigns to STMicroelectronics’ role in AI infrastructure and intelligent hardware, rather...

In February 2026, Clariane SE reported its full-year 2025 results, with sales of €5,310.3 million and net income of €1.6 million, reversing the prior year’s net loss. This shift back to profitability, achieved on only a small increase in sales from €5,281.8 million, highlights the impact of cost discipline and operational improvements. With Clariane’s return to profitability now on record, we’ll examine how this development reshapes the company’s investment narrative and outlook. Capitalize...

Veolia Environnement announced a new US hazardous waste acquisition, expanding its presence in the North American market. The company is extending its PFAS treatment capabilities across North America to address growing water quality challenges. Veolia and the National Association of Water Companies published a policy white paper calling for large scale water infrastructure investment in the US. Veolia Environnement (ENXTPA:VIE), trading at €32.4, has seen its share price return 7.5% year to...

Eurofins Scientific share performance snapshot Eurofins Scientific (ENXTPA:ERF) has drawn investor attention after recent share price moves, with the stock showing mixed short term performance and stronger longer term returns that contrast with some weaker multi year results. See our latest analysis for Eurofins Scientific. At a share price of €63.52, Eurofins Scientific has seen a 6.6% decline in its 30 day share price return after a recent pullback. Its 1 year total shareholder return of...

Ramsay Générale de Santé (ENXTPA:GDS) has released half year results to December 31, 2025, reporting sales of €2,589.1 million and a net loss of €34.9 million, both changing compared with a year earlier. See our latest analysis for Ramsay Générale de Santé. The half year update comes after a period where the share price has shown mixed momentum, with a 15.22% 90 day share price return and a 13.49% year to date share price return, yet a 3 year total shareholder return of a 45.36% decline. If...

Earnings event puts Vallourec (ENXTPA:VK) in focus Vallourec (ENXTPA:VK) is back on investors’ radar after reporting fourth quarter and full year 2025 results, with both sales and net income below the previous year’s levels, raising fresh questions about the earnings profile. See our latest analysis for Vallourec. The €19.505 share price sits against a 30 day share price return of 5.32% and a 90 day share price return of 25.68%. The 1 year total shareholder return of 30.57% and 5 year total...

In February 2026, OPmobility reported its 2025 results, with sales of €10,216 million, net income of €185 million, and basic earnings per share of €1.30, while announcing a higher annual dividend of €0.49 per share payable on April 30, 2026. Alongside these results, the company set an objective for 2026 to improve both operating margin and net result Group share compared with 2025, signalling a focus on profitability despite slightly lower sales. We’ll now examine how OPmobility’s higher...

Sanofi (ENXTPA:SAN) received FDA approval in the US for Dupixent as the first designated treatment for allergic fungal rhinosinusitis. EU regulators issued a positive opinion for Dupixent in young children with chronic spontaneous urticaria. The EU also gave a positive opinion for Acoziborole Winthrop, a single dose oral treatment for sleeping sickness in adults and adolescents. For Sanofi, these decisions touch both its core immunology franchise and its long running work in neglected...

Event context and current performance snapshot Robertet (ENXTPA:RBT) has been drawing attention after recent price moves, with the share price last closing at €825. Recent returns show a 1 day decline of 0.24%, a 7 day decline of 4.73%, and a month decline of 1.43%. See our latest analysis for Robertet. Recent selling pressure has pulled the 90 day share price return to an 8.74% decline and the year to date share price return to a 6.14% decline. The 1 year total shareholder return is 2.12%,...

Why the 2025 results and 2028 guidance matter for investors 74Software (ENXTPA:74SW) has drawn investor attention after releasing its 2025 full year results alongside fresh guidance for 2028, combining recent performance data with a clearer view of its longer term financial ambitions. On the reported figures, sales for 2025 came in at €707.22 million, while net income was €40.76 million. Basic earnings per share from continuing operations were €1.39, with diluted earnings per share at...

Viridien Société anonyme (ENXTPA:VIRI) has moved into focus after its recent earnings showed higher net income alongside lower sales, together with the rebrand from CGG that highlights its focus on Earth data and sensing. See our latest analysis for Viridien Société anonyme. Those earnings and the CGG rebrand sit against a strong recent run, with a 90 day share price return of 35.29% at €122.1 and a 1 year total shareholder return of 100.13%. This hints that momentum has been building rather...

DBV Technologies recently presented additional positive data from its successful Phase 3 VITESSE trial of the VIASKIN Peanut Patch for peanut-allergic children aged 4 to 7 at the 2026 AAAAI Annual Meeting in Philadelphia. The data showed clinically meaningful increases in the eliciting dose for treated children versus placebo, highlighting both potential protection against reactions and the risks of remaining untreated. Next, we will examine how these Phase 3 VITESSE results, particularly...

Why Planisware SAS (ENXTPA:PLNW) Is Back on Investors’ Radar Planisware SAS (ENXTPA:PLNW) has caught investor attention after issuing 2026 revenue guidance targeting low double digit growth in constant currencies and proposing a €0.36 dividend per share for 2025, a 16.1% year on year increase. The proposed €0.36 payout represents a 50% distribution of 2025 earnings, so the company is pairing its growth objectives with a commitment to return half of its profits to shareholders. See our latest...

Worldline FY 2025 results: deep losses meet modest revenue base Worldline (ENXTPA:WLN) has reported fresh numbers for FY 2025, with first half revenue of €2,204.7 million and basic EPS at a loss of €15.05. This compares with a trailing twelve month loss of €18.35 per share on €4,029.9 million of revenue. Over recent periods the company has seen revenue move from €2,368.3 million in the second half of 2023 to €2,288.9 million in the first half of 2024, then to €2,204.7 million in the first...

Ipsos (ENXTPA:IPS) has launched a €100 million share buyback programme, putting extra attention on how management is choosing to return capital and what that might mean for existing shareholders. See our latest analysis for Ipsos. The buyback follows a series of announcements, including a proposed €2.00 per share dividend, recent full year 2025 results, and changes in senior leadership and technology roles, with the share price currently at €36.92. The 30 day share price return of 11.81% and...

Société BIC (ENXTPA:BB) is back in focus after releasing its 2025 full year results, reporting lower sales, a reduced net income of €86 million, basic EPS of €2.10, and a lower dividend. See our latest analysis for Société BIC. The earnings and dividend cuts appear to be weighing on sentiment, with the share price at €54.1 and a 90 day share price return of 16.09% contrasting with a 1 year total shareholder return decline of 4.43% and a 5 year total shareholder return of 37.34%. If this...

EssilorLuxottica Société anonyme (ENXTPA:EL) in focus after recent share performance EssilorLuxottica Société anonyme (ENXTPA:EL) is drawing attention after a recent share price slide, with the stock showing negative returns over the past week, month and past 3 months. Against this backdrop, investors are weighing the company’s €28,491.0m in revenue and €2,315.0m in net income alongside its longer term total returns over 3 and 5 years. See our latest analysis for EssilorLuxottica Société...

New LNG Carrier Order Puts GTT’s Core Technology Back in Focus Gaztransport & Technigaz (ENXTPA:GTT) has just secured a new order from Samsung Heavy Industries for the design of cryogenic tanks on a 180,000 cubic meter LNG carrier, using its Mark III Flex membrane containment system. The vessel is scheduled for delivery in 2028. This contract follows earlier LNG carrier orders, including a series from Hanwha Ocean, and keeps attention on how recurring projects feed into GTT’s order book and...

On February 26, 2026, Viridien Société anonyme held a board meeting and reported fourth-quarter and full-year 2025 results, with quarterly sales of US$312 million and net income of US$52 million, and full-year sales of US$1,070.5 million alongside net income of US$71.1 million. The company’s ability to grow net income and earnings per share year-on-year despite lower sales highlights a focus on improving profitability and cost efficiency. We’ll now examine how Viridien’s higher net income...